KalVista Pharmaceuticals (NASDAQ:KALV) Issues Quarterly Earnings Results

KalVista Pharmaceuticals (NASDAQ:KALV) announced its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.05, MarketWatch Earnings reports.

Shares of NASDAQ KALV traded down $0.66 during mid-day trading on Friday, reaching $20.45. The company had a trading volume of 1,742 shares, compared to its average volume of 530,846. The stock has a market cap of $499.76 million, a PE ratio of -8.80 and a beta of 1.94. The company has a 50-day moving average price of $20.71 and a two-hundred day moving average price of $25.33. KalVista Pharmaceuticals has a 1-year low of $12.01 and a 1-year high of $45.00.

Several equities analysts have recently issued reports on KALV shares. Zacks Investment Research upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $48.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, July 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $47.43.

In other news, insider Christopher Yea sold 5,000 shares of the firm’s stock in a transaction on Monday, August 2nd. The stock was sold at an average price of $20.52, for a total value of $102,600.00. Following the completion of the sale, the insider now owns 8,234 shares of the company’s stock, valued at $168,961.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Thomas Andrew Crockett sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 1st. The stock was sold at an average price of $24.15, for a total value of $241,500.00. The disclosure for this sale can be found here. Insiders sold a total of 16,067 shares of company stock worth $376,153 over the last 90 days. Insiders own 6.40% of the company’s stock.

A hedge fund recently raised its stake in KalVista Pharmaceuticals stock. Royal Bank of Canada boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 62.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,900 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,112 shares during the period. Royal Bank of Canada’s holdings in KalVista Pharmaceuticals were worth $70,000 at the end of the most recent reporting period. 99.28% of the stock is owned by institutional investors and hedge funds.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: Gross Domestic Product (GDP)

Earnings History for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.